Stoke Therapeutics (STOK) Receivables (2024 - 2026)

Stoke Therapeutics (STOK) posted quarterly Receivables of $6.1 million for Q1 2026, down 22.31% quarter-over-quarter from $7.9 million in Q4 2025.

Stoke Therapeutics (STOK) Receivables (2024 - 2026) Analysis & Trends

Stoke Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $7.9 million, up 233.83% from the prior year.
Receivables for Q1 2026 stood at $6.1 million, down from $7.9 million in the prior quarter.
The five-year high for Receivables was $10.8 million in Q3 2025, with the low at $2.4 million in Q4 2024.
The 3-year median for Receivables is $7.0 million (2025), against an average of $6.8 million.
Peak annual rise in Receivables reached 233.83% in 2025, while the deepest fall reached 233.83% in 2025.
Stoke Therapeutics' Receivables stood at $2.4 million in 2024, then soared by 233.83% to $7.9 million in 2025, then slipped by 22.31% to $6.1 million in 2026.
Business Quant data shows STOK's Receivables at $6.1 million in Q1 2026, $7.9 million in Q4 2025, and $10.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Stoke Therapeutics	1.95 Bn	1.66 Bn	-	8.72 Mn

Download Data